AstraZeneca's Enhertu breast cancer drug added to China's state insurance list
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca's Enhertu included in China's state insurance reimbursement
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move ...
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...
Daily5h
Addition of AstraZeneca breast cancer drug Enhertu to China state insurance list
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...
AstraZeneca raised to neutral at UBS despite China headwinds
AstraZeneca (AZN) was upgraded to neutral from sell by UBS citing long-term support for the company in China despite ...
AstraZeneca Names A MSK Leader To Global Cancer Post
Dr. Bob Li, a top Asian leader from the New York-based Memorial Sloan Kettering Cancer Center, has become global head of ...
AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades
AstraZeneca Plc’s recent share-price rout has gone so far that the pharma stock has shaken off the last of its bearish ...
pharmaphorum17h
Kelun's MSD-partnered TROP2 drug gets first okay in China
which was cleared in China for TNBC in 2022. The approval means Kelun has brought its TROP2 ADC to market ahead of ...
AstraZeneca asthma drug more effective during attack than steroids, study finds
AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that ...
HUTCHMED Announces Renewal Of ORPATHYS Inclusion In China's NRDL
(RTTNews) - HUTCHMED (China) Limited (?HCM) announced that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug ...
Wall Street Journal2d
AstraZeneca Stock Falls on China Probe Fears
AstraZeneca said last week that its China chief, Leon Wang, was under investigation by authorities there, raising concerns about the stability of the company’s sales in the country, its second ...